The estimated Net Worth of Thomas D'alonzo is at least $902 Tysiąc dollars as of 14 August 2017. Thomas alonzo owns over 30,000 units of Biodelivery Sciences International stock worth over $902,109 and over the last 17 years Thomas sold BDSI stock worth over $0.
Thomas has made over 8 trades of the Biodelivery Sciences International stock since 2007, according to the Form 4 filled with the SEC. Most recently Thomas exercised 30,000 units of BDSI stock worth $167,700 on 14 August 2017.
The largest trade Thomas's ever made was exercising 30,000 units of Biodelivery Sciences International stock on 14 August 2017 worth over $167,700. On average, Thomas trades about 9,468 units every 222 days since 2007. As of 14 August 2017 Thomas still owns at least 161,379 units of Biodelivery Sciences International stock.
You can see the complete history of Thomas alonzo stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is 9048 FALLING LEAF DR., , BONITA SPRINGS, FL, 34135.
Over the last 21 years, insiders at Biodelivery Sciences International have traded over $111,671,776 worth of Biodelivery Sciences International stock and bought 1,813,177 units worth $5,352,510 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott oraz Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of $420,648. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth $29,811.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
Biodelivery Sciences International executives and other stock owners filed with the SEC include: